Initial ribociclib plus endocrine therapy for <scp>HR</scp>+/<scp>HER2</scp>− advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study
2024 · Cancer Medicine · 3 citations
https://doi.org/10.1002/cam4.7408